A pioneering pharmacokinetics and driving simulator study of APEX-52 take home microdose psilocybin
Latest Information Update: 21 Jun 2024
At a glance
- Drugs Psilocybin (Primary)
- Indications Anxiety; Depression
- Focus Pharmacokinetics
- Sponsors Apex Laboratories
Most Recent Events
- 21 Jun 2024 New trial record
- 20 Jun 2024 According to Apex Labs media release, the company announced the filing of an IND application with the U.S. Food and Drug Administration (FDA).
- 20 Jun 2024 According to Apex Labs media release, findings from the study will be used to support the development of PATHFINDER-52.